Blueprint Medicines Q1 2024 GAAP EPS $1.40 Beats $(1.66) Estimate, Sales $96.116M Beat $80.434M Estimate
Blueprint Medicines Q1 2024 GAAP EPS $1.40 Beats $(1.66) Estimate, Sales $96.116M Beat $80.434M Estimate
Blueprint Medicines 2024年第一季度GAAP每股收益爲1.40美元，超過預期（1.66美元），銷售額爲9,6116萬美元，超過80.434億美元的預期
Blueprint Medicines (NASDAQ:BPMC) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $(1.66) by 184.34 percent. The company reported quarterly sales of $96.116 million which beat the analyst consensus estimate of $80.434 million by 19.50 percent. This is a 51.87 percent increase over sales of $63.287 million the same period last year.
Blueprint Medicines（納斯達克股票代碼：BPMC）公佈的季度收益爲每股1.40美元，比分析師普遍預期的1.66美元（1.66美元）高出184.34％。該公司公佈的季度銷售額爲9,611.6萬美元，比分析師普遍預期的80.434億美元高出19.50％。這比去年同期的6328.7萬美元的銷售額增長了51.87％。